PDGFΡ−β antibody | knockout validation | Santa Cruz Biotechnology sc-1627
DOI
//dx.doi.org/10.13070/ko.en.6.1866
Date
2016-11-25

This is a knockout-validated antibody summary, based on the publication "Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis", as cited below [1] Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Goat polyclonal

Company: Santa Cruz Biotechnology

Antibody: PDGFR-β

Catalog number: Sc-1627

Summary: Goat polyclonal antibody raised against an epitope with the C-terminal region of mouse PDGFR-β. Supplier recommended for WB, IP, IF and elisa. Reacts with mouse, rat and human (weak) PDGFR-β.

Validation Method

Western blot

Sample

Lysates of NIH-3T3 and PDGF-β −/− mouse embryonic fibroblasts.

Primary incubation

Anti-PDGFR-β antibody.

Figure

See Figure 2 in [1].

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Daniels C, Wilkes M, Edens M, Kottom T, Murphy S, Limper A, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308-16 pubmed